Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.

Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for antiviral approaches that can target emerging viruses with no effective vaccines or pharmaceuticals. Here, we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (prophylactic antiviral […]

Click here to view original web page at Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.